Status:
RECRUITING
Calisthenics Versus High Intensity Interval Training in NAFL
Lead Sponsor:
Cairo University
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
30-45 years
Phase:
NA
Brief Summary
According to sample size calculation and after achieving the inclusion criteria, sixty patients with non-alcoholic fatty liver (NAFL) of both genders will be enrolled in this study and their ages will...
Detailed Description
A) Evaluation equipment: All patients will be evaluated before and after treatment protocol. 1. Body composition analyzer (in body 230):- It will be used for estimating body composition, to measure ...
Eligibility Criteria
Inclusion
- 1\. Sixty patients with non-alcoholic fatty liver disease (NAFLD) of both genders.
- 2\. Patients with mild non-alcoholic fatty liver disease (NAFLD) according to ultrasonography fatty liver indicator (US-FLI) score (2-4).( Chen et al.,2020) 3. Their age will be ranged from 30s-40s. 4. Body mass index (BMI) from 30 to 34.9 kg/m2. 5. Body free fat mass (FFM) percentage \> 25 % for men,\> 35 % for women. 6. Lean body mass (LBM) parentage \< 76 % for men; \< 69% for women. 7. Waist circumference ≥ 102 cm for men, \> 88 cm for women. 8. Waist/Hip ratio \> 0.9% for men and \> 0.8% for women. 9. Elevated liver enzymes (ALT\> 55 U/L, AST\> 48 UL, GGT\>85 U/L, AST/ALT \<1 U/L).
- 10\. Patient with dyslipidemia who has one or more from the following blood lipid values (total cholesterol \> 200 mg\\dl, LDL \> 130 mg\\dl, TG \>150 mg\\dl, HDL\< 40mg\\dl or LDL/HDL ratio \> 4).
- 11\. Low levels of physical activity (using the International Physical Activity Questionnaire- Short Version (IPAQ)) ≤ 10 min walking per day.
- 12\. Liver size estimated by ultrasonography more than 5% from the normal liver size without hepatocellular damage.
Exclusion
- The patient will be excluded if he has one of the following:-
- Unstable cardiovascular problems like arrhythmia and heart failure.
- Active Hepatitis C virus HCV.
- Diabetes mellitus (DM).
- Hypertensive patients (\>140/90mmHg).
- Active Smoker.
- Chronic chest disease.
- Patients on medications affecting muscle power as steroids.
- Auditory and visual problems.
- Pregnancy \& lactation.
- Clinically significant peripheral vascular disease (ABPI \< 80 %).
- Patients who take beta-blockers.
- Severe anemia.
- Patients with chronic renal failure.
- Musculoskeletal or neurological limitation to physical exercise.
- Any cognitive impairment that interferes with prescribed exercise procedures.
- .Participation in regular exercise training of any type in the previous 3 months
Key Trial Info
Start Date :
October 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06032650
Start Date
October 15 2023
End Date
November 1 2024
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fatma Younis Mahmoud
Giza, Egypt, 12944